daratumumab Archives - Medical Conferences

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

4 February, 2022 11:30

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

4 February, 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

4 February, 2022 11:16

ASH 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASH 2021

4 January, 2022 08:00

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

5 August, 2021 14:46

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By

Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2021

5 August, 2021 14:31

Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, APOLLO

Conference

ASH 2020

18 February, 2021 10:26

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Trial

Phase 3, CANDOR

Conference

ASH 2019

5 March, 2020 19:49

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Trial

Phase 3, ALCYONE

Conference

ASH 2019

5 March, 2020 16:16

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By

Prof. Phillippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, CASSIOPEIA

Conference

EHA 2019

9 August, 2019 23:30

Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM

Presented By

Prof. María-Victoria Mateos , University of Salamanca, Spain

Trial

Phase 3, COLUMBA

Conference

EHA 2019

9 August, 2019 21:36

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Presented By

Prof. Raymond Comenzo, Tufts University, USA

Trial

Phase 3, ANDROMEDA

Conference

EHA 2019

9 August, 2019 19:40

Daratumumab a promising treatment option for transplant-eligible multiple myeloma

Presented By

Dr Philippe Moreau, University Hospital Hôtel-Dieu, France

Trial

Phase 3, CASSIOPEIA

Conference

ASCO 2019

15 July, 2019 23:14